
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

SCHEDULE 13D
(Rule 13d-101)

**Information to be Included in Statements Filed Pursuant
to § 240.13d-1(a) and Amendments Thereto Filed
Pursuant to § 240.13d-2(a)**

**Under the Securities Exchange Act of 1934
(Amendment No. 5)**

Dynavax Technologies Corporation
(Name of Issuer)

**Common Stock, \$0.001
par value per share
(Title of Class of Securities)**

268158201
(CUSIP Number)

**Bain Capital Life Sciences Investors, LLC
200 Clarendon Street
Boston, MA 02116
617-516-2000**
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 27, 2021
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act"), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

| | | |
|--|--|--|
| 1 | Names of reporting persons Bain Capital Life Sciences Fund, L.P. | |
| 2 | Check the appropriate box if a member of a group (a) <input type="checkbox"/> (b) <input type="checkbox"/> | |
| 3 | SEC use only | |
| 4 | Source of funds WC | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e) <input type="checkbox"/> | |
| 6 | Citizenship or place of organization Cayman Islands | |
| Number of shares beneficially owned by each reporting person with: | 7 | Sole voting power 0 shares of Common Stock |
| | 8 | Shared voting power 7,634,045 shares of Common Stock |
| | 9 | Sole dispositive power 0 shares of Common Stock |
| | 10 | Shared dispositive power 7,634,045 shares of Common Stock |
| 11 | Aggregate amount beneficially owned by each reporting person 7,634,045 shares of Common Stock | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares <input type="checkbox"/> | |
| 13 | Percent of class represented by amount in Row (11) 6.4% | |
| 14 | Type of reporting person PN | |

| | | |
|--|--|--|
| 1 | Names of reporting persons BCIP Life Sciences Associates, LP | |
| 2 | Check the appropriate box if a member of a group (a) <input type="checkbox"/> (b) <input type="checkbox"/> | |
| 3 | SEC use only | |
| 4 | Source of funds WC | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e) <input type="checkbox"/> | |
| 6 | Citizenship or place of organization Delaware | |
| Number of shares beneficially owned by each reporting person with: | 7 | Sole voting power 0 shares of Common Stock |
| | 8 | Shared voting power 780,955 shares of Common Stock |
| | 9 | Sole dispositive power 0 shares of Common Stock |
| | 10 | Shared dispositive power 780,955 shares of Common Stock |
| 11 | Aggregate amount beneficially owned by each reporting person 780,955 shares of Common Stock | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares <input type="checkbox"/> | |
| 13 | Percent of class represented by amount in Row (11) 0.7% | |
| 14 | Type of reporting person PN | |

This Amendment No. 5 relates to the Common Stock of Dynavax Technologies Corporation and amends the initial statement on Schedule 13D filed by the Reporting Persons on August 22, 2019, as amended by Amendment No. 1 filed on March 12, 2020, Amendment No. 2 filed on May 28, 2020, Amendment No. 3 filed on June 11, 2021 and Amendment No. 4 filed on August 11, 2021 (the "Initial Statement" and, as further amended by this Amendment No. 5, the "Schedule 13D"). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Initial Statement.

Item 5. Interest in Securities of the Issuer

Item 5 of the Initial Statement is hereby amended and restated as follows:

The information set forth in or incorporated by reference in Items 2, 3 and 4 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

- (a), (b) As of the date hereof, (i) BC LS holds 7,634,045 shares of Common Stock, representing approximately 6.4% of the outstanding Common Stock of the Issuer, and BCIP LS holds 780,955 shares of Common Stock, representing approximately 0.7% of the outstanding Common Stock of the Issuer. As a result of the foregoing and the relationships described in Item 2 of this Schedule 13D, the Reporting Persons may be deemed to collectively beneficially own 8,415,000 shares of Common Stock as of the date hereof, representing approximately 7.1% of the outstanding Common Stock of the Issuer.

The calculation of the beneficial ownership of the Reporting Persons is based on (i) 114,760,092 shares of Common Stock issued and outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the Securities and Exchange Commission on August 4, 2021 and (ii) 4,140,000 shares of Common Stock issued by the Issuer in connection with the conversion of shares of Series B Preferred Stock held by the Reporting Persons subsequent to August 4, 2021.

- (c) On August 27, 2021, the Reporting Persons converted an aggregate of 1,891 shares of Series B Preferred Stock into an aggregate of 1,891,000 shares of Common Stock, consisting of 1,715 shares of Series B Preferred Stock held by BC LS and 176 shares of Series B Preferred Stock held by BCIP LS.

Also on August 27, 2021, the Reporting Persons sold an aggregate of 2,000,000 shares of Common Stock at a price of \$16.25 per share pursuant to Rule 144 under the Securities Act of 1933, as amended, for aggregate consideration of \$32,500,000. In the transaction, BC LS sold 1,814,290 shares of Common Stock and BCIP LS sold 185,710 shares of Common Stock.

- (d) Except as otherwise described in this Item 5, no one other than the Reporting Persons has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, any of the Common Stock beneficially owned by the Reporting Persons as described in this Item 5.
- (e) Not applicable.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: August 27, 2021

Bain Capital Life Sciences Fund, L.P.

By: Bain Capital Life Sciences Partners, LP,
its general partner

By: Bain Capital Life Sciences Investors, LLC,
its general partner

By: /s/ Andrew Hack

Name: Andrew Hack

Title: Managing Director

BCIP Life Sciences Associates, LP

By: Boylston Coinvestors, LLC,
its general partner

By: /s/ Andrew Hack

Name: Andrew Hack

Title: Authorized Signatory